0000000000149766

AUTHOR

A. Ballerini

showing 3 related works from this author

Economic Aspects in the Treatment of Schizophrenia in Italy: Cost Consequences of an Early Long-acting Injectable Anti-Psychotics (lais) Approach

2017

PurposeThe aim of this analysis was to evaluate the economic consequences of a new treatment approach in the treatment of schizophrenia in the Italian setting. In terms of direct costs, in Italy was estimated that the main driver were represented by hospitalization and residential cost (71% of total direct cost per patient), followed by semi-residential services (13%), anti-psychotic and other drugs (8%) and ambulatory services (8).MethodsA probabilistic cost consequence model was developed to estimate the potential cost reductions derived from an early treatment with atypical long-acting injectable anti-psychotics (aLAIs) drugs. A systematic literature review was carried out to identify di…

medicine.medical_specialtybusiness.industryCost consequencesHealth PolicySchizophrenia (object-oriented programming)Public Health Environmental and Occupational Healthmedicine.diseaseCost reductionPsychiatry and Mental healthIndirect costsLong actingSystematic reviewSchizophreniaEnvironmental healthmedicineScenario analysisPsychiatrybusinessEconomic consequencesEuropean Psychiatry
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct